Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV001508357 | SCV001714469 | likely pathogenic | not provided | 2021-01-26 | criteria provided, single submitter | clinical testing | PS3, PM1, PP1, PP3 |
Baylor Genetics | RCV003333161 | SCV004040949 | likely pathogenic | Hereditary spherocytosis type 2 | 2023-02-09 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003399263 | SCV004118880 | uncertain significance | SPTB-related disorder | 2023-01-13 | criteria provided, single submitter | clinical testing | The SPTB c.6068C>T variant is predicted to result in the amino acid substitution p.Ala2023Val. This variant been previously reported in the heterozygous state in individuals with hereditary elliptocytosis (reported as Ala2023Val, family CO in Parquet et al. 1994. PubMed ID: 8018926; Park et al. 2016. PubMed ID: 26830532). This variant is reported in 0.020% of alleles in individuals of Latino descent in gnomAD (http://gnomad.broadinstitute.org/variant/14-65234532-G-A). Although we suspect that this variant may be pathogenic, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Revvity Omics, |
RCV001508357 | SCV004237735 | uncertain significance | not provided | 2023-12-29 | criteria provided, single submitter | clinical testing |